Ask Warren

JONBUR Research · Update note

You're reading an earlier report from Oct 20, 2026. See the latest report

Samsung Biologics · 207940 · Biotech & Pharma

Samsung Biologics Shares Rise 18.8% in Five Days on Heavy Volume

Why this report

Written after:

  • Big price moveShares up 18.8% over 5 trading days on 2.6× normal volumeOct 19, 2026

Samsung Biologics shares rose 18.8% over five trading days to ₩1,427,000 on 2.6 times normal volume. The move lowers the valuation multiples cited in our initiation, but it does not change the company's reported financials, and the model's fair value estimate remains well below the share price.

Written Oct 20, 2026 · Data as of Oct 19, 2026 · 0 views

This is not financial advice. The report does not recommend buying or selling anything.

XfWATGr/in@

What happened

From 2026-10-13 to 2026-10-19, the shares gained 18.8% on volume 2.6 times normal. The close on 2026-10-19 was ₩1,427,000, for a market capitalization of about ₩66.1T. A news report on 2026-10-19 described the stock as the top gainer in the KOSPI pharmaceutical sector, up over 9% that day.

No new filing excerpts were provided for this move, so the filings do not explain it. Headlines around the period mention a court ruling in the company's favor restricting strikes across nine production processes, participation in the World ADC conference, and market expectations on tariffs and obesity drugs. We cannot tie the rally to any one of these from the data.

Over the past 20 days, foreign investors were net sellers of about ₩270.7B, institutions net bought about ₩213.7B and retail net bought about ₩48.8B. Foreign ownership is 12.7%, against 12.8% sixty days ago. The short balance is 0.5%. Recent filings continue to show the rights offering, the share acquisition amendment of 2026-10-16 and a supply contract, with no size details in the data provided.

Every earlier JONBUR Research report and update note on Samsung Biologics, with Pro.

Unlock with Pro

Model estimate of fair value

Bear
₩322,991
-78%
Base
₩472,202
-68%
Bull
₩709,877
-52%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Base case of the 5-year discounted cash flow model on the stock's Valuation tab (statements TTM to H1 2026; discount rate 7.5%). Bear and Bull move the main assumptions by fixed steps. See and change the assumptions

Filings and data used

Report history

  1. Oct 27, 2026Update noteModel fair value changeModel Fair Value Estimate for Samsung Biologics Rises 22.9% to ₩580,299 Base Case
  2. Oct 20, 2026Update noteBig price moveSamsung Biologics Shares Rise 18.8% in Five Days on Heavy Volume
  3. Oct 13, 2026InitiationSamsung Biologics: Profit Margins Have Expanded, but the Share Price Has Fallen Over the Past Three Months While Capital-Raising and Acquisition News Builds

Built only from jonbur's own data: prices and investor flows, filed financial statements and filings, and news headlines. Disclosed (filed) data is labelled as such. Written by AI and may contain mistakes.

This is not financial advice. The report does not recommend buying or selling anything.

Source: KRX statistical information